Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseStem Cell TransplantationTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousHematopoietic Stem CellsTransplantation ChimeraPeripheral Blood Stem Cell TransplantationTissue DonorsGraft vs Leukemia EffectBusulfanTreatment OutcomeWhole-Body IrradiationMyeloablative AgonistsRecurrenceLeukemiaBone MarrowStem CellsHistocompatibility TestingGraft vs Tumor EffectGraft SurvivalHistocompatibilityBone Marrow CellsRemission InductionVidarabineRetrospective StudiesLeukemia, Myeloid, AcuteChimerismLymphocyte TransfusionImmunosuppressive AgentsCord Blood Stem Cell TransplantationMyelodysplastic SyndromesHematologic DiseasesAnemia, AplasticPrecursor Cell Lymphoblastic Leukemia-LymphomaSiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCombined Modality TherapyLiver TransplantationHepatic Veno-Occlusive DiseaseCytomegalovirus InfectionsSurvival AnalysisSurvival RateHLA AntigensLymphocyte DepletionTime FactorsDisease-Free SurvivalMultiple MyelomaCyclophosphamideAcute DiseaseTransplantation ImmunologyMinor Histocompatibility AntigensTransplantation, IsogeneicT-LymphocytesSalvage TherapyAntilymphocyte SerumAllograftsNeoplasm, ResidualHematopoiesisHematopoietic Stem Cell MobilizationFollow-Up StudiesKidney TransplantationAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsImmunosuppressionCytomegalovirusLeukemia, MyeloidOpportunistic InfectionsLymphoproliferative DisordersFlow CytometryMice, Inbred C57BLMelphalanSevere Combined ImmunodeficiencyPrognosisMesenchymal Stem Cell TransplantationGraft RejectionImmunocompromised HostCell TransplantationCell DifferentiationPrimary MyelofibrosisCytarabineFatal OutcomeVirus ActivationCyclosporineRisk FactorsCystitisLymphoma, Non-HodgkinGanciclovirLeukemic InfiltrationGranulocyte Colony-Stimulating FactorHeart TransplantationMycosesEmbryonic Stem CellsAntineoplastic AgentsBlood Group IncompatibilityAntibodies, NeoplasmProspective Studies